The diagnosis of an autoimmune dementia requires the detection of objective improvements in cognitive decline (usually subacute in onset with a fluctuating course) after a course of immunotherapy. Serum and CSF antibody markers of autoimmunity (particularly those with neural antigen specificity) as well as other CSF markers of inflammation increase the suspicion for an autoimmune cause. The detection of neural autoantibodies should raise concern for a paraneoplastic etiology and may inform a targeted oncologic evaluation (eg, NMDA receptor antibodies are associated with teratoma). MRI, EEG, functional imaging, and neuropsychological evaluations provide objective evidence of neurologic dysfunction by which the success of immunotherapy may be measured. Most treatment information emanates from retrospective case series and expert opinion. Nonetheless, early intervention allows reversal of deficits in many patients. Chronic treatment is often required to maintain remission.
INTRODUCTION
Little is more satisfying for a neurologist than making a patient initially diagnosed with a neurodegenerative dementia well again. When evaluating a patient with a primary concern of cognitive dysfunction, a central and often challenging component of the diagnosis is determining whether the patient has a treatable (Table 4-1) or irreversible (usually neurodegenerative) disorder. Among rapidly progressive but potentially reversible disorders 1 are the autoimmune encephalopathies (where delirium is present) and autoimmune dementias (where there is no delirium, but other features considered atypical for a neurodegenerative disorder are present). Traditionally, neurologists have been reluctant to consider a diagnosis of an autoimmune cognitive disorder in the absence of delirium. However, some recent case series and clinicoserologic observations have suggested a growing appreciation for autoimmune neurologic disorders presenting with features of dementia rather than delirium. Unfortunately, these potentially reversible conditions may be misdiagnosed as being progressive neurodegenerative (currently irreversible) disorders, with devastating consequences for the patient. Clinical clues that have historically helped clinicians identify patients with autoimmune dementias include a rapidly progressive or fluctuating course, the detection of inflammatory markers in the CSF, presence of a neural-specific autoantibody, and clinical or serologic evidence of coexisting autoimmunity (in particular thyroid autoimmunity). For brevity's sake, we will refer to autoimmune cognitive impairment with or without encephalopathy as autoimmune dementia throughout the text. The incidence and prevalence of autoimmune Immunotherapy-responsive disorders of presumed autoimmune etiology; some have associated neural-specific antibodies (see Table 4 -2)
Other inflammatory CNS disorders dementias are unknown, but autoimmune and inflammatory causes account for 20% of dementia in patients younger than 45 years of age. 2 In recent years, neural-specific autoantibodies have been identified that have broadened the phenotypic spectrum of autoimmune dementias. Voltage-gated potassium channel (VGKC) antibodies are an example. 3, 4 This field is very much in its infancy, and data pertaining to the subject are limited to mostly single cases or small case series. Based on review of the literature and our experience in a dedicated autoimmune neurology clinic, we will describe in this chapter the clinical and diagnostic features of autoimmune dementias and provide a practical guide for the evaluation and treatment of patients with these disorders.
DEFINITIONS
The confusing nomenclature pertaining to autoimmune dementias reflects an evolving understanding of these disorders. Autoimmune dementias have been classified eponymously (eg, Morvan syndrome) 5 syndromically (eg, progressive encephalomyelopathy with rigidity and myoclonus), 6 serologically (eg, VGKC antibody-associated encephalopathy) 3 pathologically (eg, nonvasculitic autoimmune meningoencephalitis), 7 or by a combination of these. Both Hashimoto encephalopathy 8 and steroid-responsive encephalopathy associated with autoimmune thyroiditis 9 refer to a triad of encephalopathy, thyroid autoimmunity, and clinical improvements with corticosteroids. In some disorders, characteristic noncognitive features are salient. For example, in a patient with a history of branch retinal artery occlusions and hearing loss, as well as cognitive difficulties, the steroid-responsive endotheliopathy Susac syndrome should be considered. 10 Multifocal symptoms and signs that are common in Susac syndrome include headache, psychiatric disturbances, memory loss, and rapidly progressive dementia.
Other CNS disorders that are of unknown cause but usually classified as inflammatory may present as rapidly progressive dementia (Table 4-1) . Each has well-characterized clinical, radiologic, and pathologic diagnostic criteria and recommended treatments, and thus needs to be excluded when considering a diagnosis of autoimmune dementia. More commonly encountered examples include CNS vasculitis, multiple sclerosis (MS) and sarcoidosis. CNS vasculitis (also known as primary angiitis of the CNS) is characterized pathologically by multifocal vascular inflammation with predilection for small arteries in leptomeninges. Some patients have a coexisting amyloid angiopathy. 11 Its variable clinical features include headache, delirium, and rapidly progressive dementia. An MS relapse may be characterized by subacute cognitive decline with delirium and impaired attention, and subsequent improvements may occur during remission. 12 CNS disease is a serious and potentially devastating complication of sarcoidosis, which is an inflammatory multisystem disorder that affects the nervous system in 5% to 15% of patients. Although noncognitive syndromes (including cranial neuropathies and aseptic meningitis) are its most common CNS presentations, a subset of patients has amnesia and other cognitive deficits. 13 As the disease presentations are protean, solitary CNS sarcoidosis is often difficult to diagnose without a brain biopsy.
In the interest of simplicity we propose the following as the essence of autoimmune dementia: (1) clinical, radiologic, or serologic evidence supporting an autoimmune etiology; (2) other causes of dementia, particularly reversible causes excluded ( The clinical manifestations of neurologic autoimmunity are diverse and often multifocal. While certain disorders have been syndromically associated with certain autoantibody markers (eg, limbic encephalitis and VGKC autoantibodies), 4 a broader neurologic spectrum inevitably emerges over time through individual case reports 14 or by systematic serologic evaluation of large numbers of patients not selected by neurologic syndrome (Case 4-1).
3 For example, VGKC antibodies were initially considered to be specific for autoimmune limbic encephalitis or disorders of peripheral nervous hyperexcitability, but over time other presentations have been reported, including a rapidly progressive course mimicking Creutzfeldt-Jakob disease. 15 A personal or family history of autoimmunity or seropositivity for organ-specific (or non-organ-specific) autoantibodies is a risk factor for an autoimmune dementia. Multiple autoimmune disorders may occur in the same patient, and individuals with Continuum Lifelong Learning Neurol 2010;16 (2) 
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Case 4-1
An 82-year-old man presented to the emergency department with a 6-month history of progressive deterioration in behavior. He had become more irritable, had poor self-care, lacked insight, and was prone to aggressive outbursts. His examination was remarkable for repetitive stereotyped facial grimacing and intermittent aphasia. Although his Mini-Mental State Examination (MMSE) score was 27/30 and demonstrated normal recall, the Frontal Assessment Battery demonstrated deficits in mental flexibility, motor programming, and inhibitory control (11/18) . MRI showed mild generalized atrophy, but fluorodeoxyglucose PET demonstrated bifrontal hypometabolism. Serum VGKC autoantibody was detected. The diagnosis made was VGKC-antibody-associated encephalopathy with frontotemporal phenotype. Within 3 weeks of starting prednisolone (70 mg/d), the syndrome improved considerably and the Frontal Assessment Battery score was 17/18. After 6 months of tapering prednisolone dose, the patient was still mildly disinhibited but had resumed living independently.
Comment. This case illustrates (1) that the spectrum of cognitive disorders associated with VGKC autoimmunity extends beyond limbic encephalitis and (2) that screening with the MMSE alone may not detect cognitive deficits referable to the frontal lobes.
KEY POINT
A A personal or family history of autoimmunity or seropositivity for organ-specific (or non-organspecific) autoantibodies is a risk factor for an autoimmune dementia.
an autoimmune disease are at higher risk of developing a second autoimmune disorder. 16 For example, just as rheumatoid arthritis may occur in a patient with type 1 diabetes mellitus, so may autoimmune thyroiditis (a very common form of autoimmunity) and an autoimmune dementia (a relatively uncommon form of autoimmunity) occur in the same patient. Thus, the presence of autoimmune thyroiditis reflects a risk for developing other autoimmune diseases, including an autoimmune dementia. The detection of an organspecific (eg, thyroid) or non-organspecific antibody (eg, nuclear or extractable nuclear antigen) in a patient with an autoimmune dementia does not imply pathogenicity of the antibody detected.
Detection of a neural-specific autoantibody serves as a marker of neurologic autoimmunity. Antibodies directed at cell-surface antigens (eg, VGKC antibodies) may be pathogenic, while antibodies directed at an intracellular antigen (eg, antineuronal nuclear antibody type 1 [ANNA-1, or anti-Hu]) are more likely markers of a T-cell mediated disease. 17 An informative profile of neuralspecific autoantibodies aids the identification of a paraneoplastic etiology for an autoimmune dementia. Antibodies with neural specificity have varying degrees of paraneoplastic significance. For examples, see the later section ''Testing.' ' A trial of immunotherapy may serve as a valuable ''diagnostic test.'' The diagnosis of autoimmune dementia is somewhat dependent on clinical improvements obtained with immunotherapy. Therefore, in the evaluation of a patient with suspected autoimmune dementia, baseline objective clinical, electrophysiologic, radiologic, and neuropsychological testing provides reference points for evaluating clinical improvement with immunotherapies.
SYMPTOMS OF AUTOIMMUNE DEMENTIA
Patients with autoimmune dementias usually present with an acute or subacute disorder of memory, thinking, or behavior. A common cognitive disorder seen in an autoimmune context is limbic encephalitis. This is generally a fluctuating confusional state accompanied by one or more symptoms of memory loss, agitation, hallucinations, and focal seizures. 18 A variety of autoantibody accompaniments (Table 4-2 3,4,14,15,19-34 ) have been described. However, one or more of the full range of dementia symptoms may be encountered, including impairments in learning and retaining new information; disturbances in language, behavior, orientation, reasoning and praxis (Case 4-2); and difficulty handling complex tasks. Impairments in attention and consciousness (delirium) are common in autoimmune dementias but are not always present. Fluctuations in cognitive abilities from day to day are common in autoimmune dementias but may also be observed in patients with neurodegenerative disorders, particularly diffuse Lewy body disease. 35 Although uncommon, a history of spontaneous remission suggests an autoimmune etiology, but remission also may occur in toxic, metabolic, and psychogenic disorders, and depression. 
PERSONAL OR FAMILY HISTORY OF AUTOIMMUNITY OR CANCER AND CANCER RISK FACTORS
CLINICAL EXAMINATION
A bedside evaluation of cognitive function, such as the MMSE 36 or Kokmen Short Test of Mental Status, 37 should reveal impairments in one or more categories of attention, memory, reasoning, calculation, and praxis. The presence of multifocal neurologic symptoms and signs is a valuable clue to the possibility of an autoimmune etiology. Rapid evolution of a cognitive disorder, with accompanying epilepsy, ataxia, parkinsonism, brainstem signs, myelopathy, or a peripheral nervous system disorder, should trigger consideration of an autoimmune dementia as well as toxic, nutritional, metabolic causes, or other inflammatory disorders ( 
Case 4-2
A 79-year-old woman presented with rapid loss of function and twitching of the right upper extremity. The previous year she had been treated for locally invasive breast adenocarcinoma. Examination showed prominent myoclonus and ideomotor apraxia of the right upper extremity. Corticobasal degeneration (CBD) was initially considered, but the rapidity of symptom onset and decline in neurologic function was atypical. A cranial MRI revealed T2 signal abnormality in the left superior-posterior frontal lobe (Figure 4-1 vasculopathies, neoplasia, seizure disorders, drug effects, nutritional deficiencies, infections, metabolic disorders, and endocrine disturbances (Table 4-1).
Objective Documentation of Cognitive and Other Neurologic Abnormalities
These evaluations enable characterization of multifocal accompaniments of autoimmune dementia in an individual patient, and provide a pretreatment clinical baseline.
Neuropsychological Testing
Although not required for a diagnosis of autoimmune dementia, detailed assessment of cognitive deficits by neuropsychological testing provides objective evidence where impairments are mild (Case 4-4) and not detectable by bedside testing. It also may reveal potential mitigating factors, such as depression.
Neuroimaging
Magnetic resonance imaging. MRI may reveal abnormalities in T2-signal characteristics atypical for neurodegenerative disorders. Mesial temporal lobes are a common location for T2-signal abnormalities in autoimmune dementias, particularly in patients with VGKC autoantibodies. However, large extratemporal abnormalities are sometimes observed. 38 Subtle white matter or gyriform enhancement may be seen, but avid enhancement should raise suspicion for a primary tumor (including CNS lymphoma), sarcoidosis, or CNS vasculitis. The MRI abnormality typical of Continuum Lifelong Learning Neurol 2010;16 (2) 88 Case 4-3
A 55-year-old man with no significant previous medical history presented with abrupt onset of memory difficulty 2 years previously. The first episode was characterized by sudden inability to remember spoken directions and difficulty remembering events 6 weeks later. The patient had slow improvements after each event but never returned to normal. Personal history was remarkable for graying of hair in late teen years (poliosis). He had a sister with systemic lupus erythematous (SLE) and a strong family history of thyroid autoimmunity. The Kokmen Short Test of Mental Status revealed a score of 36/38 (2/4 for recall). MRI brain scan showed mild generalized cerebral atrophy, and EEG showed generalized mild slowing. Neuropsychological evaluation revealed moderate impairments in learning and memory; the profile was most consistent with amnestic mild cognitive impairment. Evaluation for serologic and CSF markers of autoimmunity was negative. Atypical amnestic mild cognitive impairment was diagnosed, but, because of the family history of autoimmunity, a course of IV methylprednisolone was initiated (1000 mg for 3 consecutive days, followed by 1000 mg weekly for 10 weeks). At follow-up (2 weeks after completing methylprednisolone treatment, and 4 months after initial neuropsychological evaluation) the patient reported dramatic improvement of cognition, recall was 4/4 per the Kokmen test, and learning and memory were improved significantly on neuropsychological reevaluation. There had been no recurrence of these cognitive problems 14 months after completing immunotherapy.
Comment. This case demonstrates that the spectrum of autoimmune dementias may include mild cognitive impairment, as well as florid encephalopathy. Neuropsychological evaluations performed before and after immunotherapy allowed objective assessment of the response to treatment.
Case 4-4
An adolescent girl presented with a few days of right hand numbness, arm pain, and school-related paranoia, beginning 3 days after mild upper respiratory symptoms. She was not febrile but appeared ill, had difficulty finding words, and speech was mildly slurred. On admission to intensive care, she developed involuntary repetitive hand movements predominately on the right, and periods of agitation with unresponsiveness, mutism, flailing of the right arm, drooling, and enuresis. Between episodes she appeared lucid. The CSF contained 63 white blood cells per L, with normal protein and glucose concentrations. EEG demonstrated left-sided background slowing. Brain MRI after contrast administration showed minimal sulcal enhancement. Haloperidol therapy was started to treat agitation. Hyperthermia developed 4 days later. On hospital admission she had neck dystonia, body rigidity, and opisthotonic posturing. Serum creatinine kinase level was normal. In periods of agitation the systolic blood pressure increased to 150 mm Hg. She was mute, appeared frightened, and was intermittently able to follow simple commands. Reflexes were brisk with unsustained bilateral clonus; she exhibited intermittent waxy catatonia. Lorazepam and a loading dose of levetiracetam were administered for suspected status epilepticus. Video EEG showed left-sided slowing without epileptic activity; episodes of masticatory movements and right eye deviation were captured without electrographic correlate. Infrequent episodes of oxygen desaturation were recorded, but she did not require intubation. On day 15 of the illness, NMDA receptor antibodies were detected in CSF (Figure 4-2) . A 5-day course of simultaneous IV immunoglobulin (IVIG) and methylprednisolone was started. Screening for ovarian teratoma and other systemic neoplasia was negative. The dystonia improved within 1 week, and she could stand and walk with shuffling gait, but remained disinhibited, impulsive, hyperoral, and hypersexual. Initial speech was characterized by echolalia and incoherent babbling but progressed to appropriate full sentences. Emotional lability continued, with frequent tearfulness; sleep became more erratic with nighttime awakenings but improved with clonidine. After transfer to a rehabilitation facility on day 20, episodic agitation, crying, and screaming continued. Six weeks after symptom onset, speech, behavior, and mobility were substantially improved. Eight weeks after symptom onset, neuropsychological testing revealed mild deficits in processing speed, but advanced intellectual ability was preserved. Periodic follow-up and MRI screening for ovarian teratoma continued. Comment. This case illustrates the classic neuropsychiatric presentation and appropriate oncologic screening (59% have cancer, usually teratoma 19 ) in an adolescent girl with NMDA receptor antibodies and the potential in some cases for good neurologic recovery with a short course of immunotherapy. Susac syndrome preferentially involves the central corpus callosum. 10 Rapidly resolving large hemispheric T2 abnormalities should raise concern for a mitochondrial disorder, including mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS). Nonenhancing large T2-signal abnormalities should raise consideration of progressive multifocal leukoencephalopathy. Rarer, but striking, T2-signal abnormalities usually associated with Creutzfeldt-Jakob disease, including gyriform T2-signal changes, have been observed in patients with VGKC antibodies (Figure 4-3) .
Functional imaging. PET or SPECT may reveal areas of abnormal brain metabolism corresponding to clinical symptoms. In patients with a coexisting seizure disorder of new onset, these images may give the false impression of a malignant CNS neoplasm, particularly in patients with VGKC autoimmunity. Electrophysiological testing. Although abnormalities detected are not specific for an autoimmune etiology, EEG, like functional imaging, may aid characterization of the disorder in an individual patient and provide a pretreatment baseline. Common abnormalities detected on EEG include focal or generalized slowing or spike-and slow-wave epileptiform discharges. Mesial temporal abnormalities are often observed in autoimmune dementias, but extratemporal abnormalities also have been reported. 38 Resolution of an EEG, MRI, or functional imaging abnormality after immunotherapy serves as an objective marker supporting subjective improvements (Figures 4-1 and 4 
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Testing for Further Clues to an Autoimmune (Idiopathic or Paraneoplastic) Diagnosis Autoantibody testing. Detection of autoantibodies in serum or CSF augments the information obtained in the clinical history. An informative autoantibody profile may include neural and non-neural IgG markers. Seropositivity for non-neural autoantibodies does not confirm a diagnosis of an autoimmune dementia, but does support consideration of an autoimmune pathogenesis and may trigger additional serologic evaluation and a trial of immunotherapy. For example, detection of thyroperoxidase or thyroglobulin autoantibodies in a patient with cognitive symptoms does not confirm a diagnosis of an autoimmune cognitive disorder (so-called Hashimoto encephalopathy) but is a supportive finding.
In a patient presenting with cognitive dysfunction, seropositivity for antinuclear antibodies and double-stranded DNA antibodies will raise suspicion for lupus cerebritis (or CNS lupus), a poorly understood disorder classified under the umbrella of neuropsychiatric lupus (which includes diverse diagnoses, from stroke to peripheral neuropathy in the setting of SLE). 39 Primary neurologic presentations account for 25% of lupus cerebritis cases. 40 Headache, seizures, and memory impairment are common, but movement disorders (including parkinsonism and myoclonus) have also been reported. 40 Despite sporadic literature reports, 41 no autoantibody marker has been confirmed to reliably inform which patients with SLE will develop cerebritis. Autoimmune dementia can arise in the setting of other non-organspecific autoimmune diseases, including Sjögren syndrome. 42 Similarly, no specific biomarker has been identified for CNS disease in that context.
The detection of a neural-specific antibody in serum or CSF ( Table 4 -2) aids the diagnostic process by: (1) raising suspicion for an autoimmune neurologic disorder, and (2) raising the possibility of a paraneoplastic cause for that autoimmune disorder. Clinical syndromes that are recognized with certain antibody markers include limbic encephalitis with VGKC antibodies (Figure 4-1) , ANNA-1 (anti-Hu) 25 ( Figure 4-5) , and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antibodies 22 ; fluctuating dense hemiplegia with complete recovery and thyroid autoantibodies 8 ; and early psychiatric features (anxiety, agitation, delusions, visual and auditory hallucinations) with NMDA receptor antibody (Case 4-4, Figure 4-2) . 19 However, the clinical phenotype associated with any given neural autoantibody is usually broader than the initially described ''classic'' neurologic associations. 17 The positive predictive values for rates of cancer detection (and cancer type) vary from 33% for VGKC antibodies (diverse cancer types) 3 to over 80% for ANNA-1 (almost always smallcell lung carcinoma). 25 Comprehensive testing for neural-specific autoantibodies is more informative than testing for individual antibodies, because the neurologic manifestations of paraneoplastic autoimmunity are protean and not limited to presentations cited in case reports. An individual patient's profile of coexisting autoantibodies may have high predictive value for a specific cancer. 
KEY POINT
" AUTOIMMUNE DEMENTIAS amphiphysin antibody in a woman may be associated with breast carcinoma or small-cell lung carcinoma, either pulmonary or extrapulmonary in origin. 43 Antibody tests performed on serum alone are often sufficiently informative, but CSF testing sometimes increases the diagnostic yield (eg, collapsin-response mediator-protein 5 [CRMP-5]-IgG). However, in the case of NMDAR antibodies CSF is sometimes more informative than serum. Simultaneous testing of serum and CSF is therefore recommended.
Other CSF parameters. Further clues to an autoimmune etiology for a cognitive disorder may be found on CSF evaluation. Elevated protein concentration (greater than 100 mg/dL), mild CSF pleocytosis, abnormal numbers of CSF-exclusive oligoclonal bands, and elevated IgG index and synthesis rate all support an autoimmune etiology. These CSF findings are encountered in many inflammatory CNS disorders, including MS. Oligoclonal bands are detected in 7% of patients with pathologically proven primary neurodegenerative disorders 44 and in 4% of patients with Creutzfeldt-Jakob disease. 45 Testing for Cancer Suspicion for a paraneoplastic cause of an autoimmune cognitive disorder may arise because of a risk factor identified in the history (eg, smoking or a family history of cancer) or because one or more antibodies detected have a known cancer association. In this setting, screening for cancer is warranted. In addition to a general clinical examination, CT of chest, abdomen, and pelvis in all patients, mammography in women, and testicular ultrasound and prostate-specific antigen (PSA) in men should be performed where appropriate. Certain antibodies with a particular specificity for cancer (eg, NMDAR antibody and teratoma) may further refine the diagnostic evaluation. For paraneoplastic neurologic disorders, PET imaging alone, or in combination with anatomic data (PET-CT), increases the cancer diagnostic yield by 20% when all standard evaluations (eg, whole-body CT scan) have been uninformative. 46 TREATMENT No definitive evidence-based medicine supports the use of immunotherapy for the treatment of autoimmune dementias. Available data emanates from expert opinion, 47 retrospective case series, 4, 20 and individual case reports. One prospective open-label study evaluated the efficacy of immunotherapy in 20 patients with paraneoplastic neurologic disorders, of whom only five had cognitive impairment 48 ; improvements were observed in two of three patients who received oral cyclophosphamide and plasma exchange, and in none of two patients who received plasma exchange and conventional cancer chemotherapy. Despite paucity of formal evidence, a rational therapeutic approach can be applied using treatments that have been successfully applied in a variety of autoimmune disorders. The authors typically use a protocol divided into acute (''diagnostic'') and chronic therapeutic phases. This approach is extrapolated from a combination of clinical experience and from knowledge of the therapeutic approach to other autoimmune disorders, but is not evidence based ( Table 4- Acute Therapy-The Diagnostic Test A response to immunotherapy in the acute treatment phase has diagnostic as well as therapeutic importance. The authors generally initiate a trial of highdose pulse IV corticosteroids therapy ( " AUTOIMMUNE DEMENTIAS symptoms in patients with autoimmune dementias 49 but is generally reserved for critically ill patients or when corticosteroids or IVIG is poorly tolerated.
After an initial 4-to 8-weeks trial of therapy, the patient should be reevaluated for subjective and objective evidence of clinical improvement, preferably by the same physician and in the same institution or clinic to assure test-retest consistency. This is particularly important for mental status and neuropsychological testing, in which the instruments of measure may differ from institution to institution. Patients who report feeling better following corticosteroid therapy may lack objective evidence of improvement. In patients who lack objective evidence of improvement, a trial of IVIG could be considered, again with subsequent evaluations.
In a recent study, the authors examined the clinical course and predictors of improvement in 75 patients with a predominant cognitive disorder who received immunotherapy because the treating clinician considered the possibility of an autoimmune etiology. 50 Improvements were documented in 65% of cases. Statistically significant predictors of immunotherapy-associated improvement included a subacute onset, fluctuating course, shorter delay to treatment, detection of a cation channelspecific autoantibody (VGKC, calcium channel, ganglionic acetylcholine receptor) and CSF findings of elevated protein (greater than 100 mg/dL) or pleocytosis.
Chronic Therapy
Objective improvements that translate into meaningful gains in functional abilities (eg, improvement in memory and thinking, return to work or resumption of independent living) should prompt consideration of a long-term plan for immunotherapy because symptoms relapse in most patients on withdrawal of acute therapies. General guiding principles include remission maintenance and reduction in corticosteroid or IVIG dependence when possible. The latter objective may be achieved by adding a steroid-sparing inhibitor of purine metabolism (Table 4-3) , either as oral (azathioprine, mycophenolate mofetil, cyclophosphamide, or methotrexate) or IV (cyclophosphamide) medication. The authors consider azathioprine and mycophenolate mofetil steroid-sparing agents of choice for this indication, because both have been used widely in treating organspecific autoimmune neurologic diseases, such as myasthenia gravis. 51, 52 Medium-to long-term therapy with corticosteroids or IVIG may be required in treating patients with autoimmune cognitive disorders, recognizing the multiple and often severe side effects of chronic oral corticosteroids ( Table 4-3) . Potential advantages to long-term weekly (or less frequently administered) IV corticosteroid ''pulse therapy'' over chronic oral corticosteroids may include a more benign side effect profile and safer drug cessation. 53, 54 In the authors' practice, we gradually extend the interval between infusions of IV corticosteroids or IVIG over a period of 4 to 6 months from weekly to alternate weeks, every 3 weeks, and then monthly. At that point, if the patient is not noting symptomatic deterioration or improvement coinciding with days immediately before or after an infusion, it is reasonable to discontinue these therapies and maintain oral immunosuppressants alone. Faster withdrawal of IV therapy tends to result in a relapse of cognitive impairment, particularly in the absence of a steroid-sparing immunosuppressant agent. Some patients remain dependent on intermittent IV corticosteroid or IVIG, despite optimization of oral immunosuppressant therapy. When daily oral prednisone is being used, a slow reduction from 60-mg prednisone over months is advisable.
Some overlap of treatment with corticosteroid (or IVIG) and a steroidsparing oral immunosuppressant is required, approximately 12 weeks for azathioprine and less for mycophenolate mofetil (6 to 8 weeks). 55 Use of mycophenolate is limited by expense. Careful monitoring of blood count and liver and renal function is required for patients treated with either drug, weekly for the first month, alternate weekly for 2 months, and monthly thereafter.
No data are available to inform the appropriate duration of chronic immunosuppression in autoimmune dementias, whether with corticosteroids or a steroid-sparing agent. Some patients experience spontaneous remissions, and others are dependent lifelong on immunosuppressant medication to maintain remission. The authors generally initiate a trial of immunosuppressant medication withdrawal after 2 to 3 years.
The American College of Rheumatology Task Force on Osteoporosis recommends maintaining calcium intake at 1000 mg/d to 1500 mg/d and vitamin D intake at 800 IU/d (through diet or supplements) for patients taking corticosteroids long term. 56 Prophylaxis against Pneumocystis carinii pneumonia (trimethoprim/sulfamethoxazole, 1 double-strength tablet 3 times per week) " AUTOIMMUNE DEMENTIAS also is advised for patients receiving longterm corticosteroids or a purine analog. 57 Withdrawal of chronic oral corticosteroids must be done cautiously, with guidance from an endocrinologist or internist, to avoid emergence of adrenocortical failure
PROGNOSIS
The prognosis of autoimmune dementias varies from sustained complete remission (Case 4-5) with subsequent successful withdrawal of all immunotherapy to a relapsing-remitting course marked by chronic corticosteroid dependence. While there are no recognized biomarkers predicting outcome, early aggressive treatment with immunotherapy (within 4 months) seems to improve prognosis. 20 
CONCLUSION
The identification of a cognitive disorder as having an autoimmune pathogenesis, and therefore potentially responsive to immunotherapy, is important since otherwise affected patients invariably have an unrelenting and often rapid decline. Comprehensive clinical, neuropsychological, radiologic, electrophysiologic, serologic, and CSF evaluation permits accurate characterization of the neurologic deficits, immunologic abnormalities, and risk for an underlying cancer. A favorable response to a prompt trial of immunotherapy further enables confident diagnosis and may optimize the potential for improvements. Chronicity of symptoms and a relapsing course are common, but longer-term therapy (although requiring frequent monitoring)
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Case 4-5
A 51-year-old female attorney presented with rapid onset of impaired concentration, poor memory, tremulousness, and episodic right hemianesthesia. The Kokmen Short Test of Mental Status score was 27/38, with greatest deficits in attention and recall. She had diffuse myoclonic jerks. MRI head was normal, and EEG revealed mild generalized slowing. Serologic evaluation revealed thyroid peroxidase antibodies (996 IU/mL; normal value, less than 9.0 IU/mL), and CSF evaluation was normal. Neuropsychological evaluation documented severe impairments of information-processing speed, higher-order reasoning and problem solving, naming ability, fluency, calculation, visuospatial function, and verbal memory. This global impairment in cognition was reflected in the diffuse cerebral cortical hypometabolism observed on SPECT imaging. After a 5-day course of IV methylprednisolone the patient reported subjective cognitive improvements to 90% of normal. This was confirmed objectively by the Kokmen Short Test of Mental Status (score of 37/38) and by substantial improvements on neuropsychological evaluation. A diagnosis of autoimmune dementia was made. Because persistent deficits precluded immediate return to work, the patient received IVIG 0.4 g/kg daily for 3 days, followed by 0.4 g/kg alternate weeks. Azathioprine also was started (2 mg/kg daily). After 3 months, the IVIG dosing interval was extended to every 3 weeks and later to monthly. IVIG was discontinued after 1 year, but azathioprine was continued. Slow improvement in all clinical and radiologic abnormalities occurred over a 3-year period after the initiation of immunotherapy. At last follow-up (4 years after symptom onset), the patient had resumed a successful legal practice.
Comment. This case illustrates that complete resolution of an autoimmune dementia may occur with sustained immunotherapy and careful surveillance. may permit long-term remission. Treatment of autoimmune dementias remains empirical. Controlled prospective studies are needed to determine the optimum treatments, doses, and duration of therapy.
